Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lillian Smyth

Showing results (21-30 of 21) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 21 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER StudyKomal L Jhaveri, Elgene Lim, Rinath Jeselsohn, et al.
Pageof 3

Showing results (21-30 of 21) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 21 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER StudyKomal L Jhaveri, Elgene Lim, Rinath Jeselsohn, et al.
Pageof 3